| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hwail Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,632.00 |
| 52 Week High | ₩2,410.00 |
| 52 Week Low | ₩1,550.00 |
| Beta | 0 |
| 1 Month Change | 0.68% |
| 3 Month Change | -10.58% |
| 1 Year Change | -23.02% |
| 3 Year Change | -62.74% |
| 5 Year Change | -28.00% |
| Change since IPO | -21.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| A061250 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.06% | -1.6% | -0.5% |
| 1Y | -23.0% | 10.0% | 9.5% |
Return vs Industry: A061250 underperformed the KR Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: A061250 underperformed the KR Market which returned 9.5% over the past year.
Price Volatility
| A061250 volatility | |
|---|---|
| A061250 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A061250 has not had significant price volatility in the past 3 months.
Volatility Over Time: A061250's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | n/a | Joung-Kyu Lee | www.hwail.com |
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business.
Hwail Pharmaceutical Co.,Ltd. Fundamentals Summary
| A061250 fundamental statistics | |
|---|---|
| Market cap | ₩106.10b |
| Earnings (TTM) | ₩1.92b |
| Revenue (TTM) | ₩107.87b |
0.0x
P/E Ratio0.0x
P/S RatioIs A061250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A061250 income statement (TTM) | |
|---|---|
| Revenue | ₩107.87b |
| Cost of Revenue | ₩93.79b |
| Gross Profit | ₩14.09b |
| Other Expenses | ₩12.16b |
| Earnings | ₩1.92b |
Last Reported Earnings
Mar 31, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A061250 perform over the long term?
See historical performance and comparison